Incretin therapy
Incretin therapy has been studied in 4 papers since 2025: none in people yet, 4 reviews; 3 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 5, 2026: “Glucagon-like peptide-1 receptor agonists and aesthetic surgery: perioperative safety, timing, durability and body composition”.
4 papers study it6 findingsUpdated
1 new paper in 30 daysSee all 4
What did studies of Incretin therapy find?
6Studies of Incretin therapy measured 6 outcomes; the most studied are lean mass (1 study), gastric emptying (1) and physical function (1).
Lean mass
downin humans1
1 study
Lean mass
downin humans1
Incretin therapy decreases lean mass in humans with rapid weight reduction during incretin therapy.
“loss of lean mass with rapid weight reduction”
Reviewwith rapid weight reduction during incretin therapy
Frontiers in endocrinology
Gastric emptying
downin humans1
1 study
Gastric emptying
downin humans1
Incretin therapy decreases gastric emptying in humans.
“incretin therapy introduces distinct perioperative considerations: delayed gastric emptying with possible pulmonary aspiration in symptomatic patients”
Review
Frontiers in endocrinology
Physical function
upin humans1
1 study
Physical function
upin humans1
Incretin therapy improves physical function in humans.
“associated with improvements in physical function, mobility, and health-related quality of life”
Review
Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern
Advances in therapy
Lean-to-fat mass ratio
upin humans1
1 study
Lean-to-fat mass ratio
upin humans1
Incretin therapy improves lean-to-fat mass ratio in humans.
“incretin therapies preferentially reduce fat mass, improve the lean-to-fat mass ratio”
Review
Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern
Advances in therapy
Sarcopenic obesity
downin humans1
1 study
Sarcopenic obesity
downin humans1
Incretin therapy decreases sarcopenic obesity in humans.
“Conversely, incretin therapy can reduce the prevalence of sarcopenic obesity and mitigate myosteatosis”
Review
International Health Sciences Review
Lean body mass loss
upin humans1+25% weight lost is lean mass
1 study
Lean body mass loss
upin humans1+25% weight lost is lean mass
Incretin therapy induces lean body mass loss in humans during weight loss (approximately 25% of weight lost is lean mass).
“Clinical trials and real-world EHR phenotyping confirm that these therapies induce weight loss characterized by a consistent partitioning ratio—approximately 75% fat and 25% lean mass loss.”
Reviewduring weight loss
International Health Sciences Review